Posology : מינונים

4           Dosage and administration
Dosage
The duration of treatment varies according to the indication and the severity of the infection.

Adults
250 mg once daily.
Skin infections
Recommended duration of treatment:
•       Tinea pedis (interdigital, plantar/moccasin type): 2 to 6 weeks.
•       Tinea corporis, cruris: 2 to 4 weeks.
•       Cutaneous candidiasis: 2 to 4 weeks.
Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.
Hair and scalp infections
Recommended duration of treatment:
•       Tinea capitis: 4 weeks.
Tinea capitis occurs primarily in children.
Onychomycosis
For most patients the duration of successful treatment is 6 to 12 weeks.
Fingernail onychomycosis: Six weeks of therapy is sufficient for fingernail infections in most cases.
Toenail onychomycosis: Twelve weeks of therapy is sufficient for toenail infections in most cases.
Some patients with poor nail outgrowth may require longer treatment. The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail.

Special population

Renal impairment
The use of Lamisil tablets has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section 6 Warnings and precautions Pharmacokinetic (PK)).

Hepatic impairment
Lamisil tablets are not recommended for patients with chronic or active liver disease (see section 6 Warnings and precautions).


LAM API OCT14 CL V9 COR CPO CL                                        CDS 101212, 2012-PSB/GLC-0581-s Pediatric patients
No data are available in children under two years of age (usually <12 kg).
Children weighing <20 kg           62.5 mg once daily (not achievable with a 250 mg tablet) Children weighing 20 to 40 kg 125 mg         once daily (half of a 250 mg tablet) Children weighing >40 kg           250 mg    once daily (one 250 mg tablet) 
Geriatric patients
There is no evidence to suggest that elderly patients (aged 65 years and above) require different dosages or experience different side effects than younger patients. When prescribing Lamisil tablets for patients in this age group, the possibility of pre-existing impairment of liver or kidney function should be considered (see section 6 Warnings and precautions).
Method of administration
The scored tablets are taken orally with water. They should preferably be taken at the same time each day and can be taken on an empty stomach or after a meal.
Lamisil 250 mg scored tablets are divisible and can be divided into two equal parts (i.e., 125 mg strength).
The scored tablets cannot be crushed due to a bitter taste.